ASH 2017 | MRD-guided high-dose carfilzomib treatment for multiple myeloma
The use of minimal residual disease (MRD) status in the clinic and trials is a promising, yet controversial, area of research. In this informative interview, Ola Landgren, MD, PhD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the Phase I/II clinical trial that his group is participating in (NCT02937571), which is investigating high-dose twice weekly carfilzomib treatment for multiple myeloma (MM). Interestingly, Prof. Landgren highlights how the study is using MRD as the primary endpoint and to guide the number of cycles of treatment. He also predicts the use of MRD to guide cancer therapy in future. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
